Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women
- Conditions
- Osteoporosis Postmenopausal
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2009-12-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1231
- Registration Number
- NCT00358176
- Locations
- 🇬🇧
Sanofi-Aventis, Guildford Surrey, United Kingdom
Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Smoking Cessation (STRATUS US)
- Conditions
- Smoking Cessation
- First Posted Date
- 2006-07-31
- Last Posted Date
- 2010-12-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 787
- Registration Number
- NCT00358228
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Malvern, Pennsylvania, United States
Efficacy and Safety of Dianicline Versus Placebo as an Aid to Smoking Cessation
- Conditions
- Smoking
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2008-12-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 602
- Registration Number
- NCT00356967
- Locations
- 🇸🇪
Sanofi-Aventis Administrative Office, Bromma, Sweden
Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Patients (SCCHNS)
- Conditions
- Head and Neck Neoplasms
- Interventions
- Drug: Concomitant cisplatin, 5-FU and radiotherapyDrug: Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2009-12-07
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 101
- Registration Number
- NCT00357149
- Locations
- 🇮🇹
Sanofi-Aventis, Milan, Italy
Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2006-07-25
- Last Posted Date
- 2011-10-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 53
- Registration Number
- NCT00356122
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
- Conditions
- PertussisMeningococcal MeningitisTetanusDiphtheriaPoliomyelitis
- Interventions
- Biological: Polysaccharide Diphtheria Toxoid Conjugate Vaccine
- First Posted Date
- 2006-07-21
- Last Posted Date
- 2011-08-24
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 882
- Registration Number
- NCT00355121
Insulin Analogue With Continuous Glucose Monitoring System (CGMS) Measurement
- Conditions
- Diabetes Mellitus Type 2
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2010-08-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 480
- Registration Number
- NCT00354939
Glimepiride vs Metformin as Monotherapy in Pediatric Subjects With Type 2 Diabetes Mellitus
- Conditions
- Type 2 Diabetes Mellitus
- First Posted Date
- 2006-07-19
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 100
- Registration Number
- NCT00353691
- Locations
- 🇺🇸
Sanofi-Aventis, Bridgewater, New Jersey, United States
Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal Women
- Conditions
- Osteoporosis, Postmenopausal
- First Posted Date
- 2006-07-17
- Last Posted Date
- 2009-12-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 171
- Registration Number
- NCT00353080
- Locations
- 🇸🇪
Sanofi-Aventis, Stockholm, Sweden
Risedronate in Postmenopausal Women With Low Bone Density
- Conditions
- OSTEOPOROSIS, POSTMENOPAUSAL
- First Posted Date
- 2006-07-12
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 150
- Registration Number
- NCT00351091